Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02338960 · ClinicalTrials.gov registry record · Phase 3
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3 study of Hypoactive Sexual Desire Disorder, sponsored by Palatin Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 714
- Enrollment target
- 20
- Study locations
NCT02338960 is a Phase 3 study of Hypoactive Sexual Desire Disorder that has completed, run by Palatin Technologies. The registered enrollment target is 714 participants, above the 315-participant average among 8 other Hypoactive Sexual Desire Disorder trials with a reported enrollment target (127% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT02338960, a Phase 3 study of Hypoactive Sexual Desire Disorder, has completed, sponsored by Palatin Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 714 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bremelanotide
Study Locations (20)
California
- Palatin Clinical Site 258 - Beverly Hills
- Palatin Clinical Site 256 - Garden Grove
- Palatin Clinical Site 291 - Los Angeles
- Palatin Clinical Site 270 - Oakland
- Palatin Clinical Site 210 - San Diego
- Palatin Clinical Site 251 - San Diego
- Palatin Clinical Site 272 - Sherman Oaks
- Palatin Clinical Site 253 - Tarzana
Colorado
- Palatin Clinical Site 212 - Denver
- Palatin Clinical Site 219 - Denver
- Palatin Clinical Site 243 - Lakewood
Arizona
- Palatin Clinical Site 218 - Phoenix
- Palatin Clinical Site 254 - Tucson
Connecticut
- Palatin Clinical Site 211 - New London
- Palatin Clinical Site 229 - Waterbury
Florida
- Palatin Clinical Site 204 - Aventura
- Palatin Clinical Site 273 - Coral Gables
Alabama
- Palatin Clinical Site 242 - Birmingham
Arkansas
- Palatin Clinical Site 207 - Hot Springs
District of Columbia
- Palatin Clinical Site 202 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02338960
The ClinicalTrials.gov registry entry for NCT02338960 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 714 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 315-participant average among 8 other Hypoactive Sexual Desire Disorder trials with a reported enrollment target (127% higher). The listed sponsor is Palatin Technologies, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypoactive Sexual Desire Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02338960 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT02338960 about?
NCT02338960 is a clinical study titled "2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder". A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal f...
What is the current status of trial NCT02338960?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 714 participants. The study started on 2015-01. Estimated completion is 2017-06-29.
What conditions does trial NCT02338960 study?
This clinical trial studies the following conditions: Hypoactive Sexual Desire Disorder.
What interventions are being tested in trial NCT02338960?
The interventions under investigation include: Placebo (DRUG), Bremelanotide (DRUG).
Who is sponsoring clinical trial NCT02338960?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02338960 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoactive Sexual Desire Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
COMPLETED · Phase 3
-
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
COMPLETED · Phase 3
-
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
COMPLETED · Phase 3
-
Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder
COMPLETED · Phase 2
-
A Mindfulness-based Intervention for Older Women With Low Sexual Desire
COMPLETED · NA
-
Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.